Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Epigenetics and DNA Methylation, Cancer-related gene regulation, and MicroRNA in disease regulation.
Radiomic Prediction of CCND1 Expression Levels and Prognosis in Low-grade Glioma Based on Magnetic Resonance Imaging
SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm
Pan‐cancer analysis identifies <scp><i>CD300</i></scp> molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia
Gastric Cancer Derived Mesenchymal Stem Cells Promote the Migrationof Gastric Cancer Cells Through miR-374a-5p
m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia
Integrated analysis reveals distinct molecular, clinical, and immunological features of <i>B7‐H3</i> in acute myeloid leukemia
Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes
Identification and validation of prognosis‐related <i>DLX5</i> methylation as an epigenetic driver in myeloid neoplasms
Methylation-independent <i>CRIP1</i> expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia.
PubMed 2020cited by 6position: middle
The M2 macrophage marker <i>CD206</i> : a novel prognostic indicator for acute myeloid leukemia
BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
miR-374a-5p: A New Target for Diagnosis and Drug Resistance Therapy in Gastric Cancer
Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia
MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells
H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia
Overexpression of lncRNA <em>PANDAR </em>predicts adverse prognosis in acute myeloid leukemia
Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies
Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression
Methylation‐independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia
SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
Epigenetic dysregulation of <i>ID4</i> predicts disease progression and treatment outcome in myeloid malignancies
<i>KRAS</i> overexpression independent of <i>RAS</i> mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia
Hypomethylation‐mediated <i>H19</i> overexpression increases the risk of disease evolution through the association with <i>BCR‐ABL</i> transcript in chronic myeloid leukemia
High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia
Epigenetic dysregulation of <i>NKD2</i> is a valuable predictor assessing treatment outcome in acute myeloid leukemia